Elizabeth Pietrowski, counsel in the Tech Group, advises clients in all aspects of intellectual property law and has represented a highly diverse client base ranging from small biotech start ups to major international brand name and generic pharmaceutical corporations, as well as universities. Ms. Pietrowski's experience involves technologies spanning numerous industries and scientific disciplines, including genes and gene expression systems, proteins, antibodies, vaccines, small molecules, nanotechnology, chemical synthesis, pharmaceutical formulations (capsules, tablets, orally disintegrating dosage forms, transdermal patches, injectables, and inhalation forms), drug delivery devices, methods of treatment with pharmaceuticals and neutraceuticals.
Ms. Pietrowski's practice encompasses domestic and foreign patent prosecution from drafting applications to advocating applications through issuance. She also specializes in intellectual property licensing, material transfer agreements, supply agreements, clinical trial agreements and non-disclosure agreements. Additionally, she has conducted numerous patent due diligence investigations for companies involved in corporate mergers and acquisitions.
Prior to her career in law, Ms. Pietrowski was a practicing pharmacist and her expertise in that realm is the driving force behind her specialization in life sciences-related patent law work. She continues to maintain her status as a registered pharmacist in New Jersey.
Some of Ms. Pietrowski’s recent transactions include:
Life Sciences
- Represented a university in procurement of multiple patents relating to a ground-breaking diagnostic test recently approved by the FDA.
- Represented a global generic pharmaceutical company in negotiations with a major German technology company for pharmaceutical product development.
- Ongoing representation of a major pharmaceutical companies relating to domestic and foreign patent prosecution.
Other Technology
- Represented a leading cosmetics company in patent diligence on a multi-million dollar acquisition.
- Ongoing representation of a Fortune 100 company relating to patent prosecution of financial products.
View More...
|